Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adibendan SCHEMBL9832050 | 0.95 | PDE3B (0.90) | PDE3BPDE3APDE4APDE4BPDE4C | |
| Adibendan SCHEMBL10470994 | 0.94 | PDE3B (0.88) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9677178 | 0.86 | PDE3B (0.75) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9382103 | 0.85 | PDE4A (0.74) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10375588 | 0.83 | PDE4A (0.71) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10566025 | 0.81 | PDE3B (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10532459 | 0.81 | PDE4A (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL9379359 | 0.81 | PDE3B (0.69) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10374221 | 0.81 | PDE4A (0.68) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL10373374 | 0.81 | PDE3B (0.68) | PDE3BPDE3APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-22 | — | — | US | claimed |
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | CELLIX BIO PRIVATE LIMITED (IN) | 2024-02-20 | — | — | US | claimed |
| WO-2023196821-A2 | TARGETING NEUROPOD CELL GUCY2C TO CONTROL VISCERAL PAIN AND APPETITE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-10-12 | — | — | WO | claimed |
| WO-2022190030-A1 | A TOPICAL FORMULATION FOR THE TREATMENT OF SKIN DISEASES | AVACA PHARMA PRIVATE LIMITED (IN) | 2022-09-15 | — | — | WO | claimed |
| WO-2022157587-A1 | A COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | CELLIX BIO PRIVATE LIMITED (IN) | 2022-07-28 | — | — | US | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| EP-3621593-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2020-03-18 | — | — | EP | claimed |
| WO-2019194866-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2019-10-10 | — | — | WO | claimed |
| US-6297243-B1 | TREATING OSTEOPENIA THAT ACCOMPANIES THE MENOPAUSE | NOVO NORDISK A/S (DK) | 2001-10-02 | — | — | US | claimed |
| JP-2001500865-A | — | — | 2001-01-23 | — | — | JP | claimed |
| EP-0961616-A4 | NON-HORMONAL METHOD OF CONTRACEPTION | TRUSTEES OF BOARD OF (US) | 2000-11-22 | — | — | EP | claimed |
| US-6110471-A | ADMINISTERING PHOSPHODIESTERASE FOR INHIBITION OF THE CYCLES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2000-08-29 | — | — | US | claimed |
| EP-1028690-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 2000-08-23 | — | — | EP | claimed |
| EP-1012188-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN, Wolf-Georg, Prof. Dr. (DE) | 2000-06-28 | — | — | EP | claimed |
| EP-0961616-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1999-12-08 | — | — | EP | claimed |
| WO-1999020223-A2 | LUTEINISING HORMONE ANTAGONISTS USEFUL FOR TREATMENT OF ESTROGEN DEFICIENCIES, OR AS A CONTRACEPTIVE | NOVO NORDISK A/S (DK) | 1999-04-29 | — | — | WO | claimed |
| WO-1999014239-A1 | COMPOSITION FOR TREATING DIABETES MELLITUS AND OBESITY | FORSSMANN WOLF GEORG (DE) | 1999-03-25 | — | — | WO | claimed |
| WO-1998010765-A1 | NON-HORMONAL METHOD OF CONTRACEPTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11903992-B2 | Composition comprising lidocaine, l-carnosine and dexpanthenol | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885PDE4A 1073/4885 |
| US-20220233629-A1 | COMPOSITION COMPRISING LIDOCAINE, L-CARNOSINE AND DEXPANTHENOL | VNN1, LPL, HMGB1 | PDE3B 837/4885PDE3A 296/4885PDE4A 1073/4885 |
| US-20250161243-A1 | MEF2 TRANSCRIPTIONAL ACTIVATORS TO TREAT NEUROLOGIC CONDITIONS | MEF2D, TEAD2, TEAD1 | PDE3B 2422/4885PDE3A 1978/4885PDE4A 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.